Edition:
India

Applied Genetic Technologies Corp (AGTC.OQ)

AGTC.OQ on NASDAQ Stock Exchange Global Market

4.14USD
22 Mar 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$4.14
Open
$4.36
Day's High
$4.38
Day's Low
$4.07
Volume
19,204
Avg. Vol
31,289
52-wk High
$7.50
52-wk Low
$2.26

Latest Key Developments (Source: Significant Developments)

Applied Genetic Technologies Quarterly Revenue $5.9 Million Versus $15.2 Million
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Applied Genetic Technologies Corp ::QUARTERLY REVENUE $5.9 MILLION VERSUS $15.2 MILLION.APPLIED GENETIC TECHNOLOGIES - EXPECT OPTOGENETICS PARTNER, TO FILE AN INDA WITH FDA IN FIRST HALF OF 2019.TOTAL REVENUE WAS $5.9 MILLION FOR THREE MONTHS ENDED DECEMBER 31, 2018 COMPARED TO $4.9 MILLION.QTRLY LOSS PER SHARE $0.23.  Full Article

AGTC Reports Topline Interim 6 Month Data From Phase 1/2 X-Linked Retinoschisis Clinical Study
Thursday, 13 Dec 2018 

Dec 12 (Reuters) - Applied Genetic Technologies Corp ::AGTC ANNOUNCES TOPLINE INTERIM SIX-MONTH DATA FROM PHASE 1/2 X-LINKED RETINOSCHISIS CLINICAL STUDY; TERMINATION OF BIOGEN COLLABORATION.APPLIED GENETIC- RESULTS FROM STUDY SHOW RAAV2TYF-CB-HRS1 GENERALLY SAFE, WELL-TOLERATED, BUT NO SIGNS OF CLINICAL ACTIVITY WERE OBSERVED AT 6-MONTHS.APPLIED GENETIC TECHNOLOGIES - TO REGAIN RIGHTS TO FIVE CLINICAL AND PRECLINICAL DEVELOPMENT PROGRAMS; BIOGEN TERMINATES COLLABORATION AGREEMENT.APPLIED GENETIC TECHNOLOGIES - TO REGAIN RIGHTS TO FIVE CLINICAL & PRECLINICAL DEVELOPMENT PROGRAMS; BIOGEN TERMINATES COLLABORATION AGREEMENT.APPLIED GENETIC - ON SCHEDULE TO ADVANCE ITS PHASE 1/2 CLINICAL STUDIES IN ACHROMATOPSIA,X-LINKED RETINITIS PIGMENTOSA; 3 DATA RELEASES SEEN IN 2019.APPLIED GENETIC TECHNOLOGIES CORP - BIOGEN'S TERMINATION OF COLLABORATION AGREEMENT WILL BE EFFECTIVE ON MARCH 8, 2019.APPLIED GENETIC TECHNOLOGIES - WILL DETERMINE NEXT STEPS FOR THREE DISCOVERY PROGRAMS OVER NEXT SEVERAL MONTHS.APPLIED GENETIC TECHNOLOGIES - PREVIOUS FINANCIAL GUIDANCE, EVEN IN LIGHT OF BIOGEN'S TERMINATION OF COLLABORATION AGREEMENT, REMAINS UNCHANGED.APPLIED GENETIC TECHNOLOGIES CORP - AS OF SEPT 30, 2018, CO'S CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $105.4 MILLION.APPLIED GENETIC TECHNOLOGIES - EXPECTS TOTAL CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2019, TO BE BETWEEN $65 AND $75 MILLION.  Full Article

Applied Genetic Technologies Qtrly Rev Fell To $3.6 Mln
Wednesday, 9 May 2018 

May 8 (Reuters) - Applied Genetic Technologies Corp ::QUARTERLY REVENUE $3.6 MILLION VERSUS $8.4 MILLION .QTRLY LOSS PER SHARE $0.45.Q3 EARNINGS PER SHARE VIEW $-0.41 -- THOMSON REUTERS I/B/E/S.  Full Article

Applied Genetic posts qtrly ‍net loss of $0.08​ per share
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Applied Genetic Technologies Corp :Quarterly revenue $10.3 million versus $11.8 million.Company expects total cash, cash equivalents, and investments as of june 30, 2018 to be between $85 and $100 million​.Qtrly ‍net loss per share $0.08​.  Full Article